



Stabilis



Lidocaine hydrochloride



Noms commerciaux

Jetokaine	Turquie
Lidocard	Finlande
Lidocorit	Autriche
Lidosen	Italie
Lidrian	Italie
Linisol	Belgique
Locaine	Afrique du sud
Minijet lignocaine	Grande Bretagne
Pisacaina	Equateur, Mexique
Plidocain	Pologne
Rapidocain	Suisse
Remicaine	Afrique du sud
Remicard	Afrique du sud
Xilina	Roumanie
Xylanest	Autriche
Xylesine	Suisse
Xylestesin	Brésil
Xylocain	Autriche, Canada, Danemark, Finlande, Norvège, Pologne, Suède, Suisse
Xylocaina	Brésil, Italie
Xylocaine	Australie, Belgique, Canada, Etats Unis d'Amérique, France, Grèce, Luxembourg, Malaisie, Maroc, Pays bas, Slovénie
Xylocard	Arabie Saoudite, Australie, Autriche, Belgique, Canada, Egypte, France, Portugal, Suède
Xylocitin	Allemagne
Xyloneural	Autriche, Suisse



Stabilité des solutions

		0.45 mg/ml	22°C		21			1126
		0.45 mg/ml	4°C		21			1126
		2 mg/ml	25°C		14			619
	RL	2 mg/ml	25°C		14			619

PVC		0.45 mg/ml	22°C		21			1126
PVC		0.45 mg/ml	4°C		21			1126
PVC		2 mg/ml	25°C		14			619
PVC		4 mg/ml	30°C		120			1202
PVC		4 mg/ml	4°C		120			1202
PVC	RL	2 mg/ml	25°C		14			619
PP		20 mg/ml	25°C		90			1715
PP		20 mg/ml	25°C		90			1715
PP		20 mg/ml	4°C		90			1715



Stabilité en mélange

		1 mg/ml	25°C		Bretylium tosilate : 10 mg/ml	48		705
		1 mg/ml	40°C		Bretylium tosilate : 10 mg/ml	48		705
		1 mg/ml	4°C		Bretylium tosilate : 10 mg/ml	7		705
		3,26 mg/ml	23°C-25°C		Dopamine hydrochloride : 0,8 mg/ml	24		738
		5,3 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2279
		9,1 mg/ml	23°C		Sodium bicarbonate : 7,6 mg/ml	91		3263
		9,1 mg/ml	5°C		Sodium bicarbonate : 7,6 mg/ml	91		3263
PVC		0.5 & 10 mg/ml	25°C		Tirofiban : 25 µg/ml	4		1420
PVC		1 mg/ml	25°C		Bretylium tosilate : 10 mg/ml	48		705
PVC		1 mg/ml	40°C		Bretylium tosilate : 10 mg/ml	48		705
PVC		1 mg/ml	4°C		Bretylium tosilate : 10 mg/ml	7		705
PVC		1 & 8 mg/ml	?		Ranitidine hydrochloride : 0,05 & 2 mg/ml	48		210
PVC		4 mg/ml	23°C		Flumazenil : 0,02 mg/ml	24		187
PP		10 mg/ml	-15°C		Ceftriaxone disodium : 450 mg/ml	56		279
PP		10 mg/ml	20°C		Ceftriaxone disodium : 450 mg/ml	24		279
PP		10 mg/ml	4°C		Ceftriaxone disodium : 450 mg/ml	10		279
PP		3,5 mg/ml	22°C		Epinephrine hydrochloride : 3,5 µg/ml Bleomycin sulfate : 0,75 mg/ml	1		3420
PP		3,5 mg/ml	4°C		Epinephrine hydrochloride : 3,5 µg/ml Bleomycin sulfate : 0,75 mg/ml	3		3420
PP		9 mg/ml	4-7°C		Sodium bicarbonate : 7,8 mg/ml Epinephrine hydrochloride : 9 µg/ml	7		2878

		18 mg/ml	4-7°C		Sodium bicarbonate : 7,8 mg/ml Epinephrine hydrochloride : 9 µg/ml	7		2878
		9 mg/ml	4-7°C		Sodium bicarbonate : 7,8 mg/ml	28		2878
		18 mg/ml	4-7°C		Sodium bicarbonate : 7,8 mg/ml	28		2878
		20 mg/ml	28°C		Ketamine hydrochloride : 2,5 mg/ml	48		4350
		455 mg/ml	25°C		Magnesium sulfate : 2 mg/ml	168		4457
		455 mg/ml	40°C		Magnesium sulfate : 2 mg/ml	168		4457
		3,3 mg/ml	22°C-28°C		Daptomycin : 16,7 mg/ml	2		1937
		20 mg/ml	25°C		Phenylephrine hydrochloride : 2,5 mg/ml	66		1331



Compatibilités

	Lidocaine hydrochloride : 2 mg/ml Aminophylline : 1 mg/ml	RL	619
	Lidocaine hydrochloride : 10 mg/ml	RL	4603
	Lidocaine hydrochloride : 8 mg/ml Alteplase : 1 mg/ml		92
	Lidocaine hydrochloride : 4 mg/ml Alteplase : 0.5 mg/ml		240
	Lidocaine hydrochloride : 2 mg/ml Aminophylline : 1 mg/ml		619
	Lidocaine hydrochloride : 0.13 mg/ml		1338
	Lidocaine hydrochloride : 4 mg/ml Amiodarone hydrochloride : 1.8 mg/ml		242
	Lidocaine hydrochloride : 8 mg/ml Amiodarone hydrochloride : 4 mg/ml		1036
	Lidocaine hydrochloride : 1 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
			921
	Lidocaine hydrochloride : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Lidocaine hydrochloride : 8 mg/ml Argatroban : 1 mg/ml		1963
	Lidocaine hydrochloride : 10 mg/ml Bivalirudin : 5 mg/ml		1713
	Lidocaine hydrochloride : 2 mg/ml Bretylium tosilate : 1 mg/ml	RL	619
	Lidocaine hydrochloride : 1 mg/ml Bretylium tosilate : 10 mg/ml		705
	Lidocaine hydrochloride : 2 mg/ml Bretylium tosilate : 1 mg/ml		1193
	Lidocaine hydrochloride : 2 mg/ml Bretylium tosilate : 1 mg/ml		619
	Lidocaine hydrochloride : 10 mg/ml Caffeine : 10 mg/ml		3964

	Lidocaine hydrochloride : 2 mg/ml Calcium gluconate : 2 mg/ml		619
	Lidocaine hydrochloride : 2 mg/ml Calcium gluconate : 2 mg/ml	RL	619
	Lidocaine hydrochloride Cefamandole nafate		3546
	Lidocaine hydrochloride : 5 >> 20 mg/ml Cefamandole nafate : 285 mg/ml		612
	Lidocaine hydrochloride Cefazolin sodium		499
	Lidocaine hydrochloride : 8 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
	Lidocaine hydrochloride : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
	Lidocaine hydrochloride : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Lidocaine hydrochloride : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Lidocaine hydrochloride Ceftobiprole medocaril sodium		4650
	Lidocaine hydrochloride : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Lidocaine hydrochloride : 8 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	Lidocaine hydrochloride : 10 mg/ml Cefuroxime sodium		3687
	Lidocaine hydrochloride : 1.25 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
	Lidocaine hydrochloride : 40 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
	Lidocaine hydrochloride : 20 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
	Lidocaine hydrochloride : 8 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Lidocaine hydrochloride : 1 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Lidocaine hydrochloride : 3,3 mg/ml Daptomycin : 16,7 mg/ml		1937
	Lidocaine hydrochloride Daptomycin		2271
	Lidocaine hydrochloride : 10 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Lidocaine hydrochloride : 2 mg/ml Digoxin : 1 µg/ml		619
	Lidocaine hydrochloride : 2 mg/ml Digoxin : 1 µg/ml	RL	619
	Lidocaine hydrochloride : 8 mg/ml Diltiazem hydrochloride : 1 mg/ml		524
	Lidocaine hydrochloride : 10 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
	Lidocaine hydrochloride : 4 & 8 mg/ml Diltiazem hydrochloride : 5 mg/ml		198

	Lidocaine hydrochloride : 8 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
	Lidocaine hydrochloride : 4 mg/ml Dobutamine hydrochloride : 1 mg/ml		1058
	Lidocaine hydrochloride : 2 mg/ml Dopamine hydrochloride : 0.8 mg/ml	RL	619
	Lidocaine hydrochloride : 4 mg/ml Dopamine hydrochloride : 0.8 mg/ml		738
	Lidocaine hydrochloride : 2 mg/ml Dopamine hydrochloride : 0.8 mg/ml		619
	Lidocaine hydrochloride : 4 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Lidocaine hydrochloride : 9 & 18 mg/ml Epinephrine hydrochloride : 9 µg/ml		2878
	Lidocaine hydrochloride Eptifibatide		3934
	Lidocaine hydrochloride : 20 mg/ml Etomidate : 2 mg/ml		319
	Lidocaine hydrochloride : 1 mg/ml Famotidine		397
	Lidocaine hydrochloride : 4 mg/ml Famotidine : 0.2 mg/ml		398
	Lidocaine hydrochloride : 10 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Lidocaine hydrochloride : 2 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
	Lidocaine hydrochloride : 4 mg/ml Flumazenil : 0,02 mg/ml		187
	Lidocaine hydrochloride : 8 mg/ml Fosfomycin : 30 mg/ml		4055
	Lidocaine hydrochloride : 2 mg/ml Furosemide : 1 mg/ml		1232
	Lidocaine hydrochloride : 4 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403
	Lidocaine hydrochloride : 4 mg/ml Heparin sodium : 50 UI/ml		317
	Lidocaine hydrochloride : 8 mg/ml Hetastarch : 60 mg/ml		1721
	Lidocaine hydrochloride Hyaluronidase		3184
	Lidocaine hydrochloride Hydroxocobalamin		3932
	Lidocaine hydrochloride : 10 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Lidocaine hydrochloride : 2 mg/ml Insulin : 1 UI/ml	RL	619
	Lidocaine hydrochloride : 2 mg/ml Insulin : 1 UI/ml		619
	Lidocaine hydrochloride : 8 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Lidocaine hydrochloride : 20 mg/ml Ketamine hydrochloride : 2.5 mg/ml		4350

		Lidocaine hydrochloride : 20 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Lidocaine hydrochloride : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Lidocaine hydrochloride : 10 mg/ml Levofloxacin : 5 mg/ml		1072
		Lidocaine hydrochloride : 10 mg/ml Linezolid : 2 mg/ml		1925
		Lidocaine hydrochloride : 10 mg/ml Meropenem : 50 mg/ml		4319
		Lidocaine hydrochloride : 8 mg/ml Metoprolol tartrate : 1 mg/ml		2346
		Lidocaine hydrochloride : 10 mg/ml Micafungin : 1.5 mg/ml		2108
		Lidocaine hydrochloride : 1 mg/ml Morphine sulfate : 1 mg/ml		62
		Lidocaine hydrochloride : 5 & 10 mg/ml Moxalactam : 333 mg/ml		626
		Lidocaine hydrochloride : 1 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Lidocaine hydrochloride : 0,6 mg/ml Nafcillin sodium : 20 mg/ml	 	278
		Lidocaine hydrochloride : 1 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Lidocaine hydrochloride : 4 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	 	1490
		Lidocaine hydrochloride : 4 mg/ml Nitroglycerin : 0.4 mg/ml	 	1049
		Lidocaine hydrochloride : 10 mg/ml Palonosetron hydrochloride : 50 µg/ml		2279
		Lidocaine hydrochloride Pantoprazole sodium		2090
		Lidocaine hydrochloride : 10 mg/ml Paracetamol : 10 mg/ml		4742
		Lidocaine hydrochloride : 1 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Lidocaine hydrochloride : 20 mg/ml Phenylephrine hydrochloride : 2.5 mg/ml		1331
		Lidocaine hydrochloride : 2 mg/ml Phenytoin sodium : 1 mg/ml	 	619
		Lidocaine hydrochloride : 2 mg/ml Phenytoin sodium : 1 mg/ml	RL	619
		Lidocaine hydrochloride : 8 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Lidocaine hydrochloride : 20 mg/ml Potassium chloride : 40 mEq/l	 	730
		Lidocaine hydrochloride : 20 mg/ml Potassium chloride : 40 mEq/l	RL	730
		Lidocaine hydrochloride : 2 mg/ml Procainamide hydrochloride : 1 mg/ml	 	619
		Lidocaine hydrochloride : 2 mg/ml Procainamide hydrochloride : 1 mg/ml	RL	619

		Lidocaine hydrochloride : 10 mg/ml Propafenone hydrochloride : 1 mg/ml		925
		Lidocaine hydrochloride : 10 mg/ml Propofol		660
		Lidocaine hydrochloride : 0,25 & 0,5 mg/ml Propofol : 10 mg/ml		3502
		Lidocaine hydrochloride : 20 mg/ml Propofol : 2 mg/ml		319
		Lidocaine hydrochloride : 10 mg/ml Propofol : 10 mg/ml		300
		Lidocaine hydrochloride : 1.8 mg/ml Propofol : 9 mg/ml		794
		Lidocaine hydrochloride : 1.3 mg/ml Propofol : 8.7 mg/ml		794
		Lidocaine hydrochloride : 0.23 >> 0.95 mg/ml Propofol : 9.5 mg/ml		794
		Lidocaine hydrochloride : 0,25 & 0,5 mg/ml Propofol : 10 mg/ml		2053
		Lidocaine hydrochloride : 1 & 2 mg/ml Propofol : 10 mg/ml		2053
		Lidocaine hydrochloride : 2 mg/ml Propofol : 8 mg/ml		794
		Lidocaine hydrochloride : 1 & 8 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
		Lidocaine hydrochloride : 1 & 8 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Lidocaine hydrochloride : 8 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Lidocaine hydrochloride : 8 mg/ml Streptokinase : 30000 UI/ml		92
		Lidocaine hydrochloride : 8 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Lidocaine hydrochloride : 8 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Lidocaine hydrochloride : 4 mg/ml Theophylline : 4 mg/ml		317
		Lidocaine hydrochloride : 20 mg/ml Thiopental sodium : 25 mg/ml		319
		Lidocaine hydrochloride Tigecycline		3332
		Lidocaine hydrochloride : 1 & 20 mg/ml Tirofiban : 50 µg/ml		1420
		Lidocaine hydrochloride Tirofiban		1512
		Lidocaine hydrochloride : 4 mg/ml Vasopressin : 2 & 4 UI/ml		1801
		Lidocaine hydrochloride : 2 mg/ml Verapamil hydrochloride : 0,08 mg/ml		706
		Lidocaine hydrochloride : 2 mg/ml Warfarin sodium : 2 mg/ml		315



Voie d'administration



Bibliographie

	Type	Source
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
92	Revue	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
187	Revue	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
210	Revue	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.
214	Revue	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
240	Revue	Lam XM, Ward CA, de C du M'e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
242	Revue	Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986 ; 43: 917-921.
278	Revue	Hagan RL, Carr-Lopez S, Strickland JS. Stability of nafcillin sodium in the presence of lidocaine hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 521-523.
279	Revue	Bailey LC, Cappel KM, Orosz ST. Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes. Am J Hosp Pharm 1994 ; 51: 2159-2161.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
319	Revue	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
403	Revue	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
499	Revue	Rockwell K, Burch K. Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient. Hosp Pharm 1991 ; 26: 634-635.
524	Revue	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
612	Revue	Frable RA, Klink PR, Engel GL, Mundell EE. Stability of cefamandole nafate injection with parenteral solutions and additives. Am J Hosp Pharm 1982 ; 39: 622-627.
619	Revue	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.
626	Revue	Bornstein M, Lo AY, Thomas PN, Wilham WL. Moxalactam disodium compatibility with intramuscular and intravenous diluents. Am J Hosp Pharm 1982 ; 39: 1495-1498.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
705	Revue	Lee YC, Malick W, Amann AH, Baaske DM, Shah JJ, Wagenknecht DM, Carter JE. Bretylum tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin. Am J Hosp Pharm 1981 ; 38: 183-187.
706	Revue	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.


730	Revue	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
738	Revue	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
794	Revue	Lilley EMM, Isert PR, Carasso ML, Kennedy RA. The effect of the addition of lignocaine on propofol emulsion stability. Anaesthesia 1996 ; 51: 815-818.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
925	Revue	Dupuis LL, Trope A, Giesbrecht E, Wong B. Compatibility and stability of propafenone hydrochloride with five critical-care medications. Can J Hosp Pharm 1998 ; 51: 55-57.
1036	Revue	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1049	Revue	Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305.
1058	Revue	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072	Revue	Saltmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1126	Revue	Lackner TE, Baldus D, Butler CD, Amyx C, Kessler G. Lidocaine stability in cardioplegic solution stored in glass bottles and polyvinyl chloride bags. Am J Hosp Pharm 1983 ; 40: 97-101.
1193	Revue	Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm 1983 ; 40: 1010-1012.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1202	Revue	Smith FM, Nuessle NO. Stability of lidocaine hydrochloride in 5% dextrose injection in plastic bags. Am J Hosp Pharm 1981 ; 38: 1745-1747.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1331	Revue	Das Gupta V, Steward KR. Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution. J Clin Hosp Pharm 1986 ; 11 : 449-452.

1338	Revue	Baptista RJ, Dumas GJ, Bistran BR, Condella F, Blackburn GL. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm 1985 ; 42: 777-778.
1420	Revue	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1512	Laboratoire	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1715	Revue	Storms ML, Stewart JT, Warren FW. Stability of lidocaine hydrochloride injection at ambient temperature and 4°C in polypropylene syringes. Int J Pharm Compound 2002 ; 6: 388-390.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	Revue	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	Revue	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1963	Revue	Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2053	Revue	Masaki Y, Tanaka M, Nishikawa T. Physicochemical compatibility of propofol-lidocaine mixture. Anesth Analg 2003 ; 97: 1646-1651.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.


2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271	Laboratoire	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
2279	Revue	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2346	Revue	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
2878	Revue	Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes. Can J Hosp Pharm 2009 ; 62, 5: 375-380.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3184	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product characteristics.
3249	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Mauro V.F, Alexander K.S, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3263	Revue	Donnelly R.F. Stability of buffered lidocaine in glass vials. Can J Hosp Pharm 2011 ; 64, 4: 289-290.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3420	Revue	El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P. Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology J Oncol Pharm Practice 2014 ; 21, 3: 178-187.
3502	Laboratoire	Propofol (Diprivan®) - Summary of Products Characteristics Astra Zeneca 2012
3546	Laboratoire	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3687	Laboratoire	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015

3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratoire	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3934	Laboratoire	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4350	Revue	Beiler B, Barraud D, Vigneron J, Demor? B. Physicochemical stability of an admixture of lidocaine and ketamine in polypropylene syringe used in opioid-free anaesthesia. EJHP 2019 ;0:1-5
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4457	Revue	Houlihan, S, Decarie, D, Benes, C, Cleve, R, Vidler M, Magee L.A, Ensom M.H.H, vonDadelszen P. Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. J Obstet Gynaecol Can 2016 ;38,10:936e944.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Stabilis



Lidocaine hydrochloride



Stabilité des préparations

		5 g ® = Cooper	Emulsan® 14,6 g Gomme de Guar 0,4 g	20°C		180		4344
		5 g ® = Cooper	Emulsan® 14,6 g Gomme de Guar 0,4 g	40°C		180		4344



Stabilité en mélange


		4°C		Epinephrine hydrochloride : Flacon injectable ® = (Nephron) 2,25% Tetracain hydrochloride : Flacon injectable ® = ? (Winthrop Laboratories) 12% 12,5% Oxycodone hydrochloride : Poudre 1,05 g	182	2437
	Intrasite® 86,45 g	4°C			365	2865
	Propylène Glycol >> Lipoderm® >> 100 g	25°C		Amitriptyline hydrochloride : Poudre ® = ? 2 g Gabapentine : Poudre ® = ? 6 g Ketoprofene : Poudre ® = ? 10 g	14	3971
	Propylène Glycol >> Lipobase® >> 100 g	25°C		Ketoprofene : Poudre ® = ? 10 g Gabapentine : Poudre ® = ? 6 g Amitriptyline hydrochloride : Poudre ® = ? 2 g	28	3971




Bibliographie

	Type	Source
2437	Revue	Larson TA, Uden DL, Schilling CG. Stability of epinephrine hydrochloride in an extemporaneously compounded topical anesthetic solution of lidocaine, racepinephrine, and tetracaine Am J Health-Syst Pharm 1996 ; 53: 659-662.
2865	Revue	Gebauer MG, McClure AF, Vlahakis TL. Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel Int J Pharm 2001 ; 223: 49-54.
3971	Revue	Gorman G, Sokom S, Coward L, Arnold J J. Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs. Int J Pharm Compound 2017 ; 21, 2 : 164-170.
4344	Revue	Yay? HS, Faucheron A, Dupont L, El Kouari F, Fekkar A, Bellanger A, Tilleul P. Management of diabetic foot ulcers: a 25% lidocaine topical cream formulation design, physicochemical and microbiological assessments. EJHP 2018

Stabilis



Lidocaine hydrochloride



Stabilité des préparations

10 mg Lidocaine oral topical solution USP 2%®		Diphenhydramine 3,12 mg Aluminium hydroxide 50 mg Hydroxyde de magnésium 50 mg Siméthicone 5 mg	21°C		21			3978
20 mg Lidocaine oral topical solution USP 2%®		Diphenhydramine 2,5 mg Aluminium hydroxide 40 mg Hydroxyde de magnésium 40 mg Siméthicone 4 mg	21°C		21			3978



Bibliographie

	Type	Source
3978	Revue	Kirk L.M, Brown S.D, Luu Y, Ogle A, Huffman J, O. Lewis P.O. Beyond-use dating of lidocaine alone and in two “magic mouthwash” preparations. Am J Health-Syst Pharm 2017 ; 74,9: 202-210



Dictionnaire

 Anesthésique local	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 Non précisée
 Jour	 A l'abri de la lumière
 Lumière	RL Ringer lactate
 Polyvinyl chlorure	 Glucose 5%
 Seringue polypropylène	 Aucun
 Stabilité en mélange	 Solvant
 Molécule	 Heure
 Polypropylène	 Eau pour préparation injectable
 Chlorure de sodium 0,9%	 Non précisé
 Eau ppi + bactériostatique	 Compatibilités
 Compatible	 Nutrition parentérale (mélange ternaire)
 Précipitation immédiate	 Incompatible
 Incompatibilité non précisée	 Précipitation en 2 heures
 Turbidité immédiate	 NaHCO ₃
 Solvant spécifique	 Instabilité chimique
 Précipitation en 8 heures	 Précipitation en 4 heures
 Instabilité de l'émulsion à 6 heures	 Instabilité de l'émulsion immédiate
 Instabilité de l'émulsion à 4 heures	 Voie d'administration
 Intraveineuse	 Perfusion intraveineuse
 Perfusion continue	 Intramusculaire
 Sous cutanée	 Bibliographie
 Forme dermique	 Stabilité des préparations
 Origine	 Excipient

	Tube de pommade en aluminium		Poudre
	Seringue PP orale		Gargarisme
	Spécialité pharmaceutique		Dictionnaire